Ventripoint Adds Hospital Networking Expert to Implementation Team

02/07/18 06:02 AM EST

(TheNewswire)



 

Toronto, Ontario / TheNewswire / February 6, 2018 Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that Dr. Andriy Shmatukha has joined the Ventripoint team as software developer to advance the Ventripoint products and technology.

“Medical imaging is dependent on technologies to deal with the storage, retrieval and manipulation of large image files needed for high-resolution cardiac scans and Dr. Shmatukha is an expert on these archiving protocols,” stated Desmond Hirson, President of Ventripoint.  “We are fortunate to have his many years of experience in industry and the clinical settings on our team.”

Dr. Shmatukha is a qualified network administrator with over 18 years of medical device R&D experience with emphasis on diagnostics cardiac imaging, including the development of image analysis algorithms and associated software. At his tenure at GE Healthcare he was responsible for quality assurance of clinical trials for medical software. He is an inventor on multiple patents in image analysis algorithms and device hardware. As a research engineer at Sunnybrook Health Sciences Center (Toronto, Canada), he developed DICOM application software to manipulate medical images to allow them to be analysed and stored in a hospital Picture Archiving and Communication Systems (PACS) environment. At Utrecht University Medical Center (Utrecht, The Netherlands), he developed MRI imaging procedures and image analysis algorithms for real-time MRI guidance of minimally-invasive thermal therapies.

In other news, Ventripoint announces that it has entered  into a consulting agreement for international financial and strategic advisory services with respect to international opportunities for a term of one year. Under the contract the Company has the option to pay the quarterly work fees of $30,000 in cash or in common shares, with the number of common shares being determined with reference to the market price at the time of issuance, and subject to the approval of the TSX Venture Exchange.  

About Ventripoint Diagnostics Ltd.

Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound.  The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

 

For further information, please contact:

Dr. George Adams, CEO

telephone: (519) 803-6937, email: gadams@ventripoint.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

 

Copyright (c) 2018 TheNewswire - All rights reserved.